Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer
BlueCross BlueShield Association
Record ID 32011000426
English
Authors' objectives:
The objective of this Assessment is to evaluate EGFR testing as a predictor of tumor response to the small-molecule TKI erlotinib (Tarceva®). This would allow for targeted and optimized selection of patients for TKI therapy based on the EGFR genetic profile of the tumor being treated.
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/vols/
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.